您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2020, Vol. 58 ›› Issue (7): 32-37.doi: 10.6040/j.issn.1671-7554.0.2020.0096

• • 上一篇    

miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响

马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉   

  1. 石河子大学医学院, 新疆维吾尔自治区 石河子 832000
  • 发布日期:2020-07-10
  • 通讯作者: 史晨辉. E-mail:1512905535@qq.com
  • 基金资助:
    国家自然科学基金(81660374;81772407;81760404;31760270)

Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion

MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui   

  1. Medical College of Shihezi University, Shihezi 832000, Xinjiang Uygur Autonomous Region, China
  • Published:2020-07-10

摘要: 目的 寻找并验证miR-27b-3p和SMAD1的关系,探讨miR-27b-3p对骨肉瘤细胞增殖、侵袭、迁移作用的影响,为骨肉瘤靶向治疗提供理论依据。 方法 采用生物信息学方法预测候选靶基因;应用双荧光素酶报告实验确定miR-27b-3p和SMAD1靶向关系;采用qRT-PCR法选择SAOS-2骨肉瘤细胞系。采用miR-27b-3p转染SAOS-2细胞后,分为miR-27b-3p inhibitor组、空白对照组和阴性对照组。采用MTT、Transwell迁移和侵袭实验检测miR-27b-3p对SAOS-2细胞的影响;采用Western blotting法检测沉默miR-27b-3p后SMAD1的表达量。 结果 生物信息学检测显示,miR-27b-3p与SMAD1-UTR存在结合位点;双荧光素酶报告实验显示,miR-27b-3p inhibitor组SMAD1的表达量高于阴性对照组,差异有统计学意义(P<0.05),SMAD1是miR-27b-3p的靶基因。SAOS-2细胞MTT、Transwell迁移实验和侵袭实验结果均显示,miR-27b-3p inhibitor组与空白对照组和阴性对照组细胞数相比降低,差异有统计学意义(P<0.05),miR-27b-3p inhibitor组细胞的增殖、迁移和侵袭能力降低。miR-27b-3p inhibitor组与阴性对照组SMAD1蛋白表达量相比明显降低(P<0.05)。 结论 miR-27b-3p可以通过调控SMAD1的表达促进骨肉瘤细胞增殖、迁移和侵袭作用。miR-27b-3p可能在骨肉瘤细胞中起着促癌基因作用。

关键词: 骨肉瘤, miR-27b-3p, SMAD1, 细胞增殖, 细胞迁移, 细胞侵袭

Abstract: Objective To assess the relationship between miR-27b-3p and SMAD1 and to explore the effects of MiR-27b-3p on osteosarcoma cell proliferation, invasion and migration, so as to provide theoretical basis for targeted therapy of osteosarcoma. Methods Candidate target genes were predicted with bioinformatics methods. The targeting relationship between miR-27b-3p and SMAD1 was determined with dual luciferase report experiments. The SAOS-2 osteosarcoma cell line was selected with qRT-PCR. After SAOS-2 cells were transfected with miR-27b-3p, they were divided into 3 groups: miR-27b-3p inhibitor group, blank control group and negative control group. The effects of miR-27b-3p on SAOS-2 cells were detected with MTT, Transwell migration and invasion assay. The expression of SMAD1 after miR-27b-3p silencing was determined with Western blotting. Results Bioinformatics analysis showed there were binding sites of miR-27b-3p and SMAD1-UTR. Dual luciferase experiments showed the miR-27b-3p inhibitor group had higher expression of SMAD1 than the negative control group(P<0.05), and SMAD1 was the target gene of miR-27b-3p. MTT, Transwell migration and invasion assay showed the miR-27b-3p inhibitor group had reduced cell proliferation, migration and migration than the blank control group and negative control group(P<0.05). The miR-27b-3p inhibitor group had significantly lower protein expression of SMAD1 than negative control group(P<0.05). Conclusion miR-27b-3p can promote the proliferation, migration and invasion of osteosarcoma cells by regulating the expression of SMAD1, and may play a role as an oncogene in osteosarcoma cells.

Key words: Osteosarcoma, miR-27b-3p, SMAD1, Cell proliferation, Cell migration, Cell invasion

中图分类号: 

  • R738
[1] Ferrari S, Mercuri M, Bacci G. Comment on “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols”[J]. J Clin Oncol, 2004, 17(3):131-137.
[2] Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma(EURAMOS-1): an open-label, international, randomised controlled trial[J]. Lancet Oncol, 2016, 17(10):1396-1408.
[3] Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment-Where do we stand? A state of the art review[J]. Cancer Treat Rev, 2014, 40(4):523-532.
[4] Jones KB, Salah Z, Mare SD, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma[J]. Cancer Res, 2012, 72(7):1865-1877.
[5] Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer(European Association of Urology Guideline): American society of clinical oncology clinical practice guideline endorsement[J]. J Clin Oncol, 2016, 34(16):1945-1952.
[6] 李胜,王威,李建军,等.骨肉瘤靶向治疗研究进展[J].山东医药,2019,59(22):99-102.
[7] Fadaka AO, Klein A, Pretorius A. In silico identification of microRNAs as candidate colorectal cancer biomarkers[J]. Tumour Biol, 2019, 41(11):1-15.
[8] Li J, Zhou YY, Zhao L, et al. Effect of miR-145 on migration and invasion of ovarian cancer cells[J]. Acta Academiae Medicinae Sinicae, 2019, 41(5):581-588.
[9] Shi Y, Gong W, Lu L, et al. Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells[J]. Braz J Med Biol Res, 2019, 52(11):8657.
[10] Zou J, Liao X, Zhang J, et al. Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer[J]. J Biol Regul Homeost Agents, 2019, 33(5):1377-1385.
[11] Gao YN, Ma YP. Expression analysis and epigenetics of microrna-28-5p in multiple myeloma[J].Experimental hematology, 2019, 27(5):1540-1547.
[12] Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma[J]. Ann Hematol, 2012, 91(4):553-559.
[13] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10):997-1006.
[14] Cong C, Wang W, Tian J, et al. Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma[J]. Cancer Biomark, 2018, 21(2):449.
[15] Jones KB, Salah Z, Del Mare S, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma[J]. Cancer Res, 2012, 72(7):1865-1877.
[16] 阮水良, 韩晨阳, 官俏兵, 等. IL-9通过TGF-β/Smad通路诱导胃癌MKN-45细胞上皮-间充质转化[J]. 中国病理生理杂志, 2018, 34(10):28-33. RUAN Shuiliang, HAN Chenyang, GUAN Qiaobing, et al. IL-9 induces epithelial-mesenchymal transition of gastric cancer MKN-45 cells by TGF-β/Smad signaling pathway[J]. Chinese Journal of Pathophysiology, 2018,34(10): 28-53.
[17] 刘婷. N-糖基化抑制通过调控TGFβ/Smad通路对鼻咽癌细胞株恶性生物学行为的影响及其机制研究[D].广州:南方医科大学,2017.
[18] Xu TY, Chang YS, Jin J, et al. Bone morphogeneticprotein-4-induced epithelial-mesenchymal transition and invasiveness through Smad1-mediated signal pathway in squamous cell carcinoma of the head and neck[J]. Arch Med Res, 2011, 42(2):128-137.
[19] Yang Y, Han L, He Z, et al. Advances in limb salvage treatment of osteosarcoma[J]. J Bone Oncol, 2018, 10(1):36-40.
[20] Chen S, Wang Q, Zhou XM, et al. MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor[J]. Mol Med Rep, 2016, 14(1):949.
[21] Liu Y, Cai QY, Bao PP, et al. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes[J].Breast cancer Res, 2015, 152(1):183-191.
[22] Fukumoto I, Koshizuka K, Hanazawa T, et al. The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma[J]. Int J Oncol, 2016, 49(3):1119.
[23] Kontomanolis E, Mitrakas A, Giatromanolaki A, et al. A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer[J]. Med Oncol, 2017, 34(2):20.
[24] Zhang J, Yan YG, Wang C, et al. MicroRNAs in osteosarcoma[J]. Clin Chim Acta, 2015, 444(3):9-17.
[25] 张其川, 王素芳, 王云峰, 等. miRNA-27b在骨肉瘤中的表达及其临床意义[J].临床与病理杂志, 2017, 37(12):2633-2638. ZHANG Qichuan, WANG Sufang, WANG Yunfeng, et al. Expression and clinical significance of circulating microRNA-27b in patients with osteosarcoma[J]. Journal of Clinical and Pathology Research, 2017, 37(12):2633-2638.
[26] 姚霁航. miR-27b靶向调控CDH11促进宫颈癌细胞增殖、侵袭和EMT的相关研究[D].沈阳:中国医科大学,2017.
[27] Hongxin M, Lei Z, Jingna R, et al. Myricetin inhibits migration and invasion of hepatocellular carcinoma MHCC97H cell line by inhibiting the EMT process[J]. Oncol Lett, 2019, 18(6):6614-6620.
[28] Fernanda L, José TM, Castellón Enrique A, et al. Secreted protein acidic and rich in cysteine(SPARC)induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer[J]. Asian J Androl, 2019, 21(6):557-564.
[29] 陈记军. 骨肉瘤患者血清中特异性microRNA表达谱的筛选及其临床意义的研究[D]. 南京:南京大学, 2013.
[30] Pacifici M. The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses[J]. Matrix Biol, 2018, 10(1):71-72.
[31] Ramachandran A, Vizán P, Das D, et al. TGF-β uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition[J]. Elife, 2018, 7:31756. doi: 10.7554/eLife.31756.
[32] Massague J. How cells read TGF-beta signals[J]. Nat Rev Mol Cell Biol, 2000, 1(3):169-178.
[33] Long Y, Zhu Y. Identification of FBXW7α-regulated genes in M1-polarized macrophages in colorectal cancer by RNA sequencing[J]. Saudi Med J, 2019, 40(8):766-773.
[34] Zhao X, Sun Q, Dou C, et al. BMP4 inhibits glioblastoma invasion by promoting E-cadherin and claudin expression[J]. Front Biosci(Landmark Ed), 2019, 24(1):1060-1070.
[35] Nokin MJ, Bellier J, Durieux F, et al. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer[J]. Breast Cancer Res, 2019, 21(1):11.
[1] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 58(7): 7-14.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!